Carly, a patient at Cincinnati Children’s endocrinology department, her first infusion of Tzield, Friday, April 11, 2025, at the Burnet Campus in Cincinnati. Tzield is FDA-approved to delay the onset of insulin-dependent (Stage 3) type 1 diabetes for a specific group of patients with diabetes. Patients must be eight years or older in stage 2.

World Leaders in Treating Diabetes and Endocrine Disorders

Our pediatric diabetes and endocrinology experts offer a complete approach to treating children with rare and complex endocrine disorders.